Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Haleon plc

Haleon is a consumer health company that focuses on delivering better everyday health with humanity. The company claims to be well positioned to help individuals through its strong portfolio of brands built on science and human understanding.

Haleon

Pharmaceutical Manufacturing

Haleon HealthPartner (HCP)

Manufacturing

Voltarol GB

Consumer Services

Haleon Re/Wire Health Studio

Haleon | 240,656 followers on LinkedIn. Better everyday health with humanity 💚 | You have loved and trusted our brands for over 170 years. We have a clear purpose, to deliver better everyday health with humanity. 💚
Our category-leading brands include Sensodyne, Panadol, Centrum, TUMS, Advil, Otrivin and Voltaren. We combine deep human understanding and trusted science to make everyday health more inclusive, more achievable and more sustainable.

Andrew Gould

Agnes Adusz

Head of HR EMEA and LATAM at Haleon

Jooyong Lee

VP & General Manager Great Britain and Ireland

Bas Vorsteveld

The World Health Organization (WHO) has identified climate change as a fundamental threat to human health, with 3.6 billion people already living in areas highly susceptible to climate change. In addition to the steps we are taking to be a more sustainable business, we are also actively involved in initiatives that help consumers better understand the impacts of climate change on their everyday health. Learn more about some of the ways we are doing this here: https://lnkd.in/dX8yar2i #ClimateChangesHealth #Haleon

Our CEO Brian McNamara returned to CNBC 's Mad Money show this week with Jim Cramer . They spoke about the real momentum in the business and the exciting opportunity ahead for #Haleon .

Happy Diwali to all those celebrating. #Diwali #Haleon

We’re delighted to welcome Dawn Allen as Haleon’s new Chief Financial Officer. Dawn joins us from Tate & Lyle plc where she was CFO and member of the Executive Team and Board. Prior to this, Dawn spent 25 years at Mars Inc. where she was more recently Global CFO and Vice President of Global Transformation. Welcome to Haleon, Dawn! Learn more here: https://lnkd.in/dpTBHKdh

Haleon’s Health Inclusivity Screener is a new AI powered tool which can help address the inclusivity gap. It’s the only data driven tool of its kind to analyse digital advertising content for both readability and inclusivity metrics. These insights will help Haleon to deliver digital content which is accessible, easy to understand, and which reflects the millions of consumers we serve globally. 83% of global advertisements fail to meet basic accessibility standards, while 54% of consumers saying they don’t feel culturally represented in online advertising. We’re committed to taking action to help close the health inclusivity gap. That includes addressing health literacy, accessibility and representation within healthcare advertising. Learn more about how our Panadol brand has used the tool here: https://lnkd.in/dKAtVY9z

As part of its Actions to Breathe Cleaner initiative, Otrivine has partnered with England Athletics to develop Clean Air Guidance aimed at reducing runners’ exposure to air pollution. The recent, long-standing Potters ‘Arf Marathon in Stoke-on-Trent, UK, was the first race in the UK to adopt this guidance, supporting runners’ health and raising awareness about air pollution. #CleanAirRace #Otrivine #ActionstoBreatheCleaner

At Haleon, we remain committed to promoting inclusive health systems. Last week, our Chief Marketing Officer Tamara Rogers , took part in a panel discussion on the subject alongside the World Health Summit held in Berlin, Germany. We joined forces with the independent policy institute Chatham House , to discuss how to foster trust and resilience in the health sector amidst a fractured geopolitical environment. The panel concluded that if countries and the public and private sectors work together to foster a more inclusive approach to health, the effects could be transformative in achieving global health and equity targets. A huge thanks to Emma Ross , Helen Clark , Monique Vledder and Judy Stenmark for being part of this important conversation. #WorldHealthSummit #HealthInclusivity #Haleon

Meet some of the people whose dedication and expertise helped make Sensodyne Clinical White toothpaste a trusted choice for sensitive teeth and whitening. Hear the incredible story of the product from the perspectives of Franck, Emma, Nadeen and Charlie who have all worked on bringing this innovation to our shelves. Charlie Parkinson, Global Medical Affairs Director for Sensodyne at Haleon says "Seeing the product on the shelf, we are very proud but equally it reminds you of the team you were part of.” #Haleon #Sensodyne #ClinicalWhite #Podcast #OralHealth #Innovation

Can you have whiter teeth while managing sensitivity at the same time? In the second episode in our podcast series Happy Healthy Humans by Haleon, we’re talking about Sensodyne’s new product Clinical White. This episode features an insightful conversation with Charlie Parkinson, Global Medical Affairs Director for Sensodyne at Haleon and we discuss teeth whitening. Learn about the journey of this remarkable product from concept to market. Tune in now on Spotify and Apple podcasts. Spotify: https://lnkd.in/eWfbA7DC Apple podcasts: https://lnkd.in/ebJ9wvKU #Haleon #Sensodyne #ClinicalWhite #Podcast #OralHealth #Innovation

Osteoarthritis is a leading cause of disability, impacting quality of life for 595 million people globally. We want to play a leading role in developing better health outcomes for those affected, so we’ve teamed up with the University of Sydney to launch a five-year research fellowship. This programme will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital technologies that improve mobility. As a global leader in pain relief and vitamins, minerals and supplements – through brands like Panadol, Voltaren, Centrum and Caltrate – we’re collaborating and driving innovation to find new and better ways of managing this chronic condition. #haleon #innovation

	Mar '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Jun '23	Dec '23	Mar '24	Jun '24
account payables		1.37B -	3.14B 129.51%	3.55B 12.86%		3.62B -	3.51B -	3.53B -		3.60B -
accumulated other comprehensive income loss	26.11B -		-11.50B -						16.61B -	-11.02B 166.34%
cash and cash equivalents	-334M -	414M 223.95%	383M 7.49%	1.33B 248.30%	-1.09B 181.86%	606M 155.49%	490M -	1.04B -	-1.04B 200%	531M 150.86%
cash and short term investments	334M -	414M 23.95%	383M 7.49%	1.33B 248.30%	1.09B 18.14%	684M 37.36%	490M -	1.04B -	1.04B 0%	531M 49.14%
common stock		1M -	1M 0%	1M 0%		92M -	92M -	92M -		91M -
deferred revenue			242M -
deferred revenue non current		281M -		228M -		362M -	381M -	346M -
deferrred tax liabilities non current		3.36B -	3.47B 3.43%	3.65B 5.27%		3.60B -	3.44B -	3.49B -
goodwill		8.25B -				8.40B -
goodwill and intangible assets		27.20B -	27.69B 1.83%	28.54B 3.07%		28.44B -	27.67B -	26.86B -		26.37B -
intangible assets		18.95B -	27.69B 46.14%			20.04B -				26.37B -
inventory		951M -	986M 3.68%	1.15B 16.53%		1.35B -	1.50B -	1.41B -		1.46B -
long term debt		87M -	9.36B 10,662.07%	9.92B 5.93%	11.35B 14.47%	10.00B 11.89%	8.77B -	8.80B -		7.50B -
long term investments		23M -	8M 65.22%	43M 437.50%	321M 646.51%	69M 78.50%	87M -	101M -		87M -
net debt	334M -	577M 72.75%	9.06B 1,470.19%	8.92B 1.56%	13.13B 47.20%	9.83B 25.10%	9.38B -	8.41B -	1.04B 87.59%	8.47B 711.69%
net receivables			13.91B -							2.14B -
other assets
other current assets			18M -		-1.09B -					581M -
other current liabilities		1.97B -	1.80B 8.19%	318M 82.37%	-684M 315.09%	312M 145.61%	380M -	458M -		518M -
other liabilities					-684M -
other non current assets	-334M -	8M 102.40%	24M 200%	45M 87.50%	-321M 813.33%	132M 141.12%	113M -	114M -	-1.04B 1,015.79%	371M 135.54%
other non current liabilities		8M -	313M 3,812.50%	6M 98.08%	160M 2,566.67%	22M 86.25%	22M -	53M -		3.57B -
othertotal stockholders equity	111M -	-11.63B 10,579.28%		-11.48B -		-10.49B -	-10.88B -	-10.96B -	123M 101.12%
preferred stock				300K -
property plant equipment net		1.66B -	1.69B 1.50%	1.77B 5.04%		1.90B -	1.85B -	1.90B -		1.86B -
retained earnings		37.99B -	38.21B 0.59%	38.38B 0.43%		26.73B -	27.24B -	27.47B -		27.53B -
short term debt		904M -	80M 91.15%	335M 318.75%	684M 104.18%	437M 36.11%	1.10B -	656M -		1.51B -
short term investments	668M -	1M 99.85%			2.18B -	78M 96.43%			2.09B -
tax assets		312M -	314M 0.64%	203M 35.35%		220M -	241M -	265M -
tax payables		237M -	242M 2.11%	236M 2.48%		210M -	297M -	288M -
total assets		34.45B -	45.02B 30.69%	45.01B 0.04%	11.51B 74.42%	34.81B 202.40%	34.16B -	34.05B -		33.40B -
total current assets	334M -	5.25B 1,472.16%	15.30B 191.33%	14.40B 5.88%		4.06B -	4.20B -	4.82B -	1.04B 78.33%	4.71B 351.15%
total current liabilities		4.24B -	5.03B 18.59%	4.20B 16.45%	684M 83.71%	4.37B 538.89%	4.99B -	4.64B -		5.62B -
total debt		991M -	9.44B 852.88%	10.25B 8.58%	12.04B 17.40%	10.44B 13.27%	9.87B -	9.46B -		9.01B -
total investments	668M -	1M 99.85%	8M 700%	43M 437.50%	321M 646.51%	147M 54.21%	87M -	101M -	2.09B 1,967.33%	87M 95.83%
total liabilities		7.97B -	18.17B 128.00%	18.01B 0.92%	11.51B 36.06%	18.36B 59.45%	17.60B -	17.33B -		16.69B -
total liabilities and stockholders equity	26.22B -	34.45B 31.38%	45.02B 30.69%	45.01B 0.04%	11.51B 74.42%	34.81B 202.40%	34.16B -	34.05B -	16.73B 50.88%	33.40B 99.63%
total non current assets	-334M -	29.20B 8,842.51%	29.73B 1.80%	30.61B 2.96%	321M 98.95%	30.76B 9,481.31%	29.96B -	29.24B -	-1.04B 103.57%	28.69B 2,847.70%
total non current liabilities		3.73B -	13.15B 252.21%	13.81B 5.01%	11.51B 16.61%	13.99B 21.50%	12.61B -	12.69B -		11.06B -
total stockholders equity	26.22B -	26.36B 0.50%	26.71B 1.35%	26.89B 0.69%		16.33B -	16.45B -	16.61B -	16.73B 0.74%	16.60B 0.77%

COM:HALEON

Haleon

Last Close

357.20

13/11 17:10

Market Cap

305.73M

Beta: -

Volume Today

17.56M

Avg: -

Preview